摘要
目的探索中重度稳定型慢性阻塞性肺疾病患者吸入噻托溴铵与口服复方甲氧那明的治疗效果及安全性。方法从上海市奉贤区奉城医院2017年5月至2019年5月期间收治慢阻肺患者中选择90例作为研究对象,随机将其分为治疗组(噻托溴铵组)和对照组(复方甲氧那明组),治疗组采用噻托溴铵吸入治疗,对照组采用复方甲氧那明口服治疗,一年后观察各组患者有效率、不良情况发生率以及呼吸功能相关指标变化情况。结果治疗组治疗有效率为73.33%,对照组有效率为53.33%,FEV1/FVC、FVC、FEV1、呼吸困难评分、6 min步行试验等指标两组间存在明显差异,且均具有统计学意义(均P<0.05);和对照组比较,治疗组不良反应发生率仅为8.89%,对照组高达15.56%,且异有统计学意义(P<0.05)。结论临床在治疗中重度稳定性COPD患者时,合理应用复方甲氧那明或噻托溴铵均有不错的疗效,但噻托溴铵疗效更优,且不良反应发生率少,可在临床上推广应用。
Objective To explore the efficacy and safety of inhalation of tiotropium bromide and oral compound methoxyphenamine in patients with moderately and severely stable chronic obstructive pulmonary disease.Methods Ninety patients with chronic obstructive pulmonary disease were randomly divided into treatment group(tiotropium bromide group)and control group(compound methoxyphenamine group)from May 2017 to May 2019.The treatment group was treated with inhalation of tiotropium bromide,while the control group was treated with oral compound methoxyphenamine.One year later,the effective rate,incidence of adverse events and breathing of each group were observed.Changes of functional related indicators.Results The effective rate of treatment group was 73.33%,and that of control group was 53.33%.There were significant differences in FEV1/FVC,FVC,FEV1,dyspnea score and 6-minute walking test between the two groups(all P<0.05).Compared with the control group,the incidence of adverse reactions in the treatment group was only 8.89%,and that in the control group was as high as 15.56%,with statistical significance(P<0.05).Conclusion In the treatment of moderately and severely stable COPD patients,the rational use of compound methoxynamine or tiotropium bromide has good curative effect,but tiotropium bromide has better curative effect and fewer adverse reactions,which can be popularized and applied in clinic.
作者
叶锋
刘艳
YE Feng;LIU Yan(Shanghai Fengcheng Hospital of Fengxian District,Shanghai,201400,China)
出处
《医药论坛杂志》
2020年第7期97-100,共4页
Journal of Medical Forum
